Description
Springer 33rd Hemophilia Symposium Hamburg 2002 1st Editon 2004 Softbound by I. Scharrer, W. Schramm
HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2001/2002 Survey).- Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Annual Survey 2002.- »New Viruses« and the Safety of Factor Concentrates and Stable Blood Products: TT Virus and West Nile Virus as Current Examples.- A Retrospective Study on the Development of Inhibitors after Continuous Infusion of Factor VIII.- Characterization of Factor VIII-Inhibitory Antibodies Using Phage Display.- Rituximab — A new Treatment of Acquired Hemophilia A?.- Thrombin Generation and Thrombogram: Assays for Monitoring Factor VIII Bypassing Therapies.- Rehabilitation — A Topic for Hemophiliacs?.- Functional Analysis as a Basis for Optimizing Physiotherapy in Hemophilic Children.- Sport and Physical Fitness Recommendations for Young Hemophiliacs.- Pain Versus Clinical and Radiological Assessment in Hemophilic Arthropathies.- Endogenous Thrombin Potential in Platelet-Rich Plasma — New Insights Regarding the Different Action of F VIII and F IX.- Interactive and Case-Based Training of Diagnostic Skills and Therapeutical Management of Coagulation Disorders with CAMPUS, a Computer-Based Program.- Elevated Fibrinogen is a Risk Factor for Arterial Thrombosis in Children.- Increased von-Willebrand-Factor-Binding to Platelets in Neonatal Plasma.- Neonatal Protein C Deficiency after massive thromboembolic Event of the right upper Limb Treatment with Protein C Concentrate.- IMMUNATE S/D — A new Factor VIII — von-Willebrand-Factor Complex Concentrate.- Favorable Response to Protein C in Venoocclusive Disease after Allogeneous Stem Cell Transplantation.- Phase III Clinical Evaluation of rAHF-PFM Prepared Using a Plasma/Albumin free Method.- Anti-Prionin IgG, Possible new Serum Markers for Contact and Infection with Transmissible Spongiform Encephalopathies: Preliminary Results from Screening 100 Blood Donors.- Experimental Approaches to Hemophilia Gene Therapy: Gene Transfer into Hematopoietic Stem Cells.- Von-Willebrand-Factor Cleaving Protease (ADAMTS-13) Activity in Various Thrombotic, Hemolytic and Autoimmune Disorders.- Treatment with Interferon Alpha-2a in Patients with Hepatitis C and Hemophilia.- Practical Experiences with Therapies for Chronic Hepatitis C in Hemophilia Patients.- Deep Venous Thrombosis of the Lower Extremity in a 16-Year-old Girl with Homozygous MTHFR- and Heterozygous Factor V Leiden-Mutation.- Clinical Manifestations of Patients with Highly Elevated Anticardiolipin Antibodies.- Progression of an Extensive Deep Vein Thrombosis Under High Dose Therapy with low Molecular Weight Heparin of a 13-4 Year-old Girl Suffering from Colitis Ulcerosa.- Hyperfibrinolysis in Hemophagocytic Lymphohistiocytosis.- Prolonged Lysis-Therapy of an Arteria Iliaca Externa Thrombosis in a very low Birth Weight Infant with a Variant in the Factor-XIII-Gene.- Modified Immunsuppression in a Case of Acquired Hemophilia — Case Report.- Life-Threatening Bleeding after Vaccination as a First Manifestation of Hemophilia A.- Administration of Protein C-Concentrate (Ceprotin, Baxter) in Purpura Fulminans as the First Clinical Manifestation of Galactosemia.- Case Report: Successful Treatment of a Spontaneous Acquired Inhibitor against Factor VIII in a 73-Year old Patient.- Medical Need and Quality of Life in Patients with Hemophilia A.- Quality of Life Autoevaluation of Hemophilia Patients in Romania.- Valproate-Induced Type I von-Willebrand’s Disease — a Common Occurrence?.- Bleeding Symptoms in Carriers of Hemophilia A — Association to the Factor VIII Gene Mutation?.- Recombinant Human Interferon ?-2b Therapy, for Refractory Immune Thrombocytopenic Purpura in Children.- Review on Bleeding Episodes in Hemophiliacs Receiving no Primary Prophylactic Replacement Therapy.- Endogenous Thrombin Potential and Thrombin Activatable Fibrinolysis Inhibitor in Patie